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ABSTRACT 
 
Crystal polymorphism is the capacity of a solid crystalline form to exist in more than one structural 
arrangement. In the pharmaceutical setting investigations into the polymorphic forms of potential drugs are of 
vital importance since different crystalline forms can affect bioavailability, mechanical, thermal, and chemical 
properties. One such example is isonicotinic acid-(1-phenylethylidene) hydrazide (IPH), a derivative of the 
popular drug isoniazid (used as first line treatment against Mycobacterium tuberculosis) was found to crystallise 
in six different polymorphic forms. Each crystal structure was determined using X-ray diffraction techniques 
and including the thermal phase relationships of the polymorphic compound were delineated. In addition to 
polymorph elucidation, isonicotinic acid-(1-phenylethylidene) hydrazide was modified with –OH and –NH2 at 
various aromatic positions, creating geometric pyridyl isomers. In-depth studies of these pyridyl isomers 
revealed a diverse range of supramolecular aggregates. Preliminary thermal screening suggests that only a small 
selection of these pyridyl isomers present potential polymorphic activity for further study.  
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CHAPTER 1 INTRODUCTION 
This chapter briefly introduces the medicinal discovery of isonicotinic acid hydrazide and important functional 
groups contained within isonicotinic acid hydrazide derivatives. The following section introduces the main 
aspects of this project: structural manipulation of the isonicotinic acid hydrazide derivatives by applying 
concepts including crystal engineering, polymorphism and molecular interactions. The final section will discuss 
hypotheses and aims of this project. 
1.1 Background to isonicotinic acid hydrazide (isoniazid) 
Isonicotinic acid hydrazide (isoniazid) (Figure 1) was first prepared by Meyer and Malley in 1912 from ethyl 
isonicotinate and hydrazine.
1
 Only in 1945 were its biological properties discovered when it was shown that 
nicotinamide had anti-Mycobacterium tuberculosis (TB) properties. This sparked the search for other  pyridine 
derivatives with activity against TB.
2
 TB subsequently developed strong resistance against the isoniazid drug 
which led to the search for isoniazid derivatives to combat the drug resistance.
3
 At the time of drug resistance, 
derivatised forms of isoniazid such as isonicotinic acid-(1-phenylethylidene) hydrazide (IPH) (prepared from 
isoniazid and acetophenone) (Figure 2) were solely developed to combat TB. However such derivatised 
isoniazid compounds (and geometric isomers shown in Figure 3) now contains the functional group hydrazone 
(R1R2C=NNH2). This hydrazone belongs to a larger Schiff base family containing the azomethine -NHN=CH 
functional group, a broad range anti-microbial enhancing functional group.
4
  
 
Figure 1: Parent structure of the nicotinamide based anti-TB drug isoniazid. 
 
 
Figure 2: Isonicotinic acid-(1-phenylphenylethylidene) hydrazide (IPH) prepared from isoniazid and acetophenone. 
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Figure 3: Pyridyl isomers of isoniazid: nicotinic acid hydrazide (A) and picolinic acid hydrazide (B). 
In addition the hydrazone scaffold is considered a very important pharmacophore responsible for antimicrobial 
activity.
5
 The International Union of Pure and Applied Chemistry (IUPAC) defines a pharmacophore as “an 
ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions 
with a specific biological target and to trigger (or block) its biological response”.6 The hydrazine group is 
considered a viable lead structure for the synthesis of drugs with broad spectrum and more efficacious 
antimicrobial activity.
5
 The hydrazone functional group provides a backbone for numerous condensation 
reactions in benzo-fused N-heterocycles which allows for further development of critical new drugs.
7
 
Furthermore, established drugs containing the hydrazone functional group display anticonvulsant properties 
which can potentially open a new path for the treatment of epilepsy.
8
 Therefore, N-isonicotinoyl arylketone 
hydrazones are an excellent group of compounds for solid state crystalline manipulation. 
1.2 Solid-state crystalline manipulation 
1.2.1 Crystal engineering 
Crystal engineering is the attempt at pre-meditated control and design of crystal structures from organic, 
inorganic and hybrid species.
9
 Crystal engineering is applied by understanding principles of intermolecular 
interactions that dominate in molecular solids in order to fine-tune their optical, magnetic or electronic 
properties, or simply to increase the knowledge base for the design of crystals.
10
 The nascent field of crystal 
engineering can be extended to intermolecular assemblies such as the rational design of supramolecular 
polymers, protein ligand identification, drug delivery systems, as well as non-crystalline solids that have a 
degree of molecular organization.
11
 Although the fundamental question in crystal engineering remains: ‘What is 
the crystal structure of an organic compound, when solely provided with the molecular structure?’ this question 
can be rephrased as ‘During a crystallization event, do molecules recognise one another?’. Currently there is no 
general answer to this question but it can be dissected into smaller questions that may shed light on the situation 
as shown below:
12
   
One → Few → Many → Crystal 
 
The above schematic implies that the crystallization process is initiated by a few molecules that assemble to 
form a cluster, which may then aggregate to form larger clusters.
12
 After which a nucleation event occurs when 
these larger clusters interact with one another, which in turn leads to the creation of the first crystal.
12
 When 
crystals are built up from a large number of molecules, the crystallization is not necessarily a smooth and 
continuous process in which the final structure of the crystal is established.
13
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The larger and smaller clusters possess local order which eventually leads to long-range order and periodicity 
associated with the crystalline state. However, the when and how of the crystallization process is complicated, 
and details of the timing largely remain unknown.
14
 A small cluster may not exemplify a good model for a 
larger aggregate, as the process leading up to nucleation may contain discontinuities in the process of building 
up of clusters into nucleation and growth of a crystal.
15
 Ultimately it becomes a difficult task to observe and 
understand the molecule-to-crystal progression.
16
 Despite the difficulties faced in crystal engineering, the field 
can be broken down into three stages to provide a framework for de-convoluting the crystallisation process. The 
three stages of study are: (i) the study of intermolecular interactions; (ii) a strategy for crystal construction in the 
context of the packing modes and these intermolecular interactions; and (iii) the study of crystal properties.
17
  
These stages concurrently form the basis for supramolecular synthesis which is used in controlling crystal 
formation outcomes. 
1.2.2 Supramolecular synthesis 
The central dogma of supramolecular chemistry states that, just as atoms are built up and connected with 
covalent bonds to form a molecule, a supramolecule is built up with molecules, and intermolecular interactions 
are used as connectors between these molecules.
18
 In other words crystal engineering can be considered as a 
form of solid state supramolecular synthesis since it is the design and construction of a molecular crystal.
19
 
Furthermore, crystallization is likened to supramolecular reaction (involving supramolecular synthons) where 
the crystal nucleus can be compared to a conventional transition state.
20
 The required supramolecular synthons 
are defined as structural units that show the fundamental features of a crystal structure as well as encapsulate 
molecular recognition in crystals.
21
 These synthons consist of molecular fragments (functional groups) and 
contain a variety of supramolecular associations (intermolecular interactions) (see Section 1.3) between them 
that direct the assembly. Predominantly the directional specificity of the hydrogen bonds is utilised.
22
 Self-
assembly of supramolecular arrays occurs when crystallization takes places and these supramolecular arrays will 
pack according to the most thermodynamically stable packing arrangement at a given temperature.
23
 However, 
the kinetic product can potentially crystallise in a pseudo-stable state first, and may not necessarily be the most 
thermodynamically stable form.
23
 
1.3 Intermolecular interactions  
Intermolecular interactions play a crucial role in the determination of the molecular arrangement in a crystal.
24
 
Specific molecular arrangements are stabilised by these interactions, which are then able to cause changes in 
torsion angles, resulting in different conformations.
25
 The most stabilised molecular conformation is the most 
stable equilibrium conformation, but various molecular conformations can have similar energy. The most 
important interaction for isoniazid derivatives and derivatised structural isomers is the hydrogen bond. As stated 
in a recent review by Nangia, “The hydrogen bond is the most important of all directional intermolecular 
interactions”,25 as the hydrogen bond is operational in a large variety of molecular aggregations.25 The hydrogen 
bond is the most cohesive directive force in organic molecules and is considered a very strong bond with the 
typical bonding values of about 4 – 15  kcal mol-1 for standard  hydrogen bonds such as O-H···O, N-H···O, or 
O-H···N.
25
 Hydrogen bonding resembles the start of proton transfer reactions where the typical hydrogen bond 
D-H···A, D-H is the proton donor and A is the proton acceptor (commonly referred to as donor and acceptor).
26
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Other weaker non-covalent intermolecular interactions include C-H···O hydrogen bond, π···π, as well as X···X 
(X = halogen) and C-H···π interactions.24  In a typical hydrogen bond only a single donor and acceptor interact 
(Figure 4a) however a donor can also simultaneously interact with two or three acceptors (Figure 4b, c). A 
trifurcated hydrogen bond is not a common occurrence as stringent conditions are required.  
 
 
Figure 4:  Hydrogen bond bridges. a) Typical hydrogen bond with a single donor and acceptor. b) Bifurcated hydrogen bond 
with two acceptors. c)  Trifurcated hydrogen bond involving a single donor with three acceptors.  
 
The schematic diagram of the hydrogen bond potential energy versus distance between donor and acceptor 
atoms in Figure 5 shows that a stabilising interaction (that is, with E > 0) is associated with a repulsive force if it 
is shorter than the equilibrium distance. Negative and positive bond energies of hydrogen bonding are described 
by the terms stabilising (i.e. bonding) and destabilising (i.e. anti-bonding), respectively.
26
 Figure 5 shows the 
typical hydrogen bond of stabilising (E < 0) and destabilising (E > 0) interactions. The hydrogen bond potential 
is a stabilising interaction when the equilibrium distance is longer than the associated repulsive force.
26
 If the 
attraction interaction has a distance of d > d0 and the repulsion interaction has a distance of d < d0 then this 
implies that the hydrogen bond length differing in length from d0 will force a geometry to tend to lower 
energy.
26
 Energies in the range of 0.5-10 kcal mol
-1 
are similar to both intramolecular torsions and 
intermolecular non-bonded interactions.
27
 Therefore there is a very strong possibility that polymorphism (see 
Section 1.4) in conformationally flexible systems can occur with relative ease.
27
 Strong hydrogen bonding may 
be optimised when the geometry of the new polymorph causes multiple subtle deformations that lead to extreme 
deformation of one torsion angle.
28
 This then causes the overall crystal packing to be influenced by molecular 
conformation and hydrogen bonding.
29
 Depending on the molecular environments the packing arrangements 
may be rearranged into closely related or disparate molecular structures resulting in the occurrence of 
polymorphism.     
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Figure 5: A schematic representation of the hydrogen bond potential energy versus distance between donor and acceptor 
atoms, d. Taken from reference 26. 
1.4 Polymorphism 
 
Since the middle of the 18
th
 century it has been known that substances can crystallise into more than one 
form; however the topic of polymorphism of drug compounds has received extensive attention only 
recently by academia and industry, including the much publicised debate by patent lawyers.
30
 It is well 
known that the adoption of a particular crystalline structure has profound influence over the solid-state 
properties of a compound. This was illustrated by early pioneering reports of Aguiar and colleagues at 
Parke–Davis where polymorphism was shown to influence the bioavailability and dissolution rates of 
chloramphenicol palmitate.
31, 32
 The influence on solid-state properties is not limited to dissolution
33
 and 
bioavailabilities
34
 only, but has extensive influence on melting points,
35
 mechanical processing,
36
 shelf-
life,
37
 and meta-stabilities.
38
 Polymorphism is now a well-established phenomenon in the development 
of drug compounds as it is of essential importance to understand and control the development of which 
polymorph is obtained, as the change in the solid-state properties of one form to another may have 
drastic consequences in the manufacturing processes in pharmaceutical production.
39
 In addition, 
different polymorphs may influence every stage of drug compound development starting from pre-
clinical stages to post marketing phase of the drug product, including patent protection.  
 
Polymorphism is the manner in which a compound can rearrange itself in 3-D space in such a way as to 
have different packing arrangements or different conformational arrangements.
40-42
. Furthermore 
conformational polymorphism is where a flexible molecule can rearrange itself to produce more than 
one different conformation in the solid state.
42
 However, most often both packing and conformational 
differences are observed among two or more different polymorphs.
43
 The conformation of organic 
compounds is a subtle but an important property in polymorphism.
25
 As the polymorphs can be 
interconverted by solid-to-solid phase transformations or via a solvent-mediated process; phase 
transformations can also be induced by heat or mechanical stress.
44
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When developing such drug compounds it is crucial to develop an understanding of the phase 
transformation relationships between various polymorphic forms. This enables drug developers to 
determine the most stable form and whether the desired form with the most beneficial solid-state 
properties will remain stable throughout the lifespan of the drug compound. The importance of 
polymorphs in a research and commercial setting is that they are able to exhibit many different physical 
properties, for example melting points and crystals habits. More importantly in the pharmaceutical 
industry, a change in compressibility and/or solubility of a potential drug candidate can greatly 
influence tableting procedures as well as bioavailability properties.
45
 Polymorphism is mostly found in 
organic molecules such as alkanes, aromatic π-bonded systems, amino acids and carboxylic acids.43 
Contrary to popular belief, the crystal structures described by researchers are not necessarily 
supramolecular aggregates that have a minimum in the global free energy of the solid-state, as some 
polymorphic forms are actually metastable states, i.e. the kinetic product (Figure 6).
46
 This kinetic 
product is described by Ostwald: “When leaving a metastable state, a given chemical system does not 
seek out the most stable state, rather the nearest metastable one that can be reached with minimum loss 
of free energy”.46  
 
Figure 6: The metastable state (1) then moves to a transitional configuration (2) and finally to a stable state having 
minimum energy (3). Taken from reference 46. 
 
Additionally, Gibbs free energy differences between polymorphs are usually minimal.
47
 Particularly between 
room temperature and the melting point, one polymorph can be the thermodynamically stable form.
47
 Whilst 
others may exist as meta-stable forms for an extended period of time, or may spontaneously convert into a more 
stable form. These conversions are called phase transitions in solids and have been classified as either first or 
second order transitions.
48
 First-order transitions involve two phases in equilibrium at transition temperature, 
with a discontinuous change of any physical property.
48
 The phase transition is believed to occur by nucleation 
of one phase, followed by its growth over another phase.
49
 In second-order transitions there is no discontinuity 
in the volume or entropy at transition temperature, and are usually order-disorder transitions which are 
associated with a change in the degree of order in the solid.
50
 
1.4.1 Types of polymorphism 
The stability of polymorphic forms (in relation to temperature and pressure) are categorised into two 
relationships: monotropic or enantiotropic (Figure 7).
51
 For a monotropic relationship, one polymorphic form is 
stable with a lower Gibbs free energy over the entire temperature and pressure range below its melting point, 
whilst the other polymorphic forms are metastable.
52
  
7 
 
The enantiotropic relationship occurs when one polymorphic form is stable over a certain temperature and 
pressure range, and may undergo a conversion into another polymorphic form that is stable over a different 
temperature range and pressure.
53
 In the enantiotropic system, polymorph A has lower free energy (GA) than 
polymorph B and is stable below the transition temperature (Tt).
53
 As the temperature surpasses the transition 
point temperature, polymorph B has lower free energy (GB) than that of polymorph A; thus polymorph B 
becomes more stable than polymorph A.
54
 At the transition temperature where the free energy curves for 
polymorphs A and B intersect, a reversible phase transition is observed.
54
 In contrast in the monotropic system, 
the free energy for polymorph A is less than that of the free energy of polymorph B throughout the entire 
temperature range below its melting point.
54
 The free energy curves do not intersect and hence this system does 
not exhibit a reversible phase transition between polymorphs A and B below the melting points of both 
polymorphs.
55
 However, at sufficient energy below the melting point, an irreversible phase transition may occur, 
where polymorph B melts followed by the crystallization of polymorph A as the most thermodynamically stable 
form.
55
 On a final note, monotropic and enantiotropic relationships can be distinguished by determining the 
heats of fusion of the polymorphic forms.
55
 
 
Figure 7: Free energy vs. temperature diagrams for the enantiotropic (left) and monotropic (right) systems for solid phases 
of polymorphic forms A and B. The enthalpies (heats of fusion) are represented with red arrows. Taken from reference 61.  
1.4.2 Characterisation of polymorphs  
Analytical methods are used to characterise the different polymorphic forms, ranging from complete structural 
determination to melting point determination. Microscopic methods are used to study the morphology of 
crystals, as well as observing changes within crystal forms such as phase transitions with a change in 
temperature. Solid state NMR and vibrational spectroscopy are used to interpret molecular motion as well as the 
chemical environment. X-ray diffraction (single crystal and powder) provides unambiguous structural 
information where single crystal XRD provides atomic positions and complete structural information, and 
powder XRD provides solid state nature and purity of a bulk microcrystalline sample. Lastly, characterisation of 
the interrelationships of polymorphic forms can be quantified by thermal analysis. This includes differential 
scanning calorimetry (DSC), differential thermal analysis (DTA) and thermogravimetry. 
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1.5 The effect of solvent on the crystallization process 
Crystallization of polymorphs from solvents may be under the control of kinetic or thermodynamic conditions.
56
 
In the case of thermodynamic conditions, there are three types of behavioral patterns are recognised that show 
dependence on nucleation and the specific polymorph’s growth rate.57 The three types of behavioral patterns 
are: i) at all concentrations the most stable polymorph form would crystallise preferentially; ii) the less stable 
polymorph form would crystallise out preferentially only at high concentrations; and iii) at intermediate 
concentrations the less stable polymorph form would crystallise out.
58
  However the current (brute force) 
methodology for the determination of polymorphs for a given compound is to attempt to crystallise the 
compound from as many solvents as possible, without concern for the above situations, i.e. regardless of 
concentration.  
The selectivity of a certain polymorph from solution is not a trivial process and the prescribed crystallization 
behavioral patterns do not exemplify a concrete law as the selected of one polymorph over another can result 
from many other factors other than crystallization that are not well understood.
59
  
1.6 Hypotheses and aims  
The hypotheses for this project are as follows: 
 Preliminary studies performed by Dr Lemmerer at University of the Witwatersrand suggest that IPH 
has six polymorphs. Therefore a crystal structure for each of the six polymorphs can be obtained.  
 The thermal phase relationship between each polymorph can be elucidated and quantified. 
 The polymorphic space will be altered when the highly polymorphic isoniazid derivative is modified 
with additional hydrogen bond donors and acceptors.  
The aims of this project are as follows: 
 To synthesize isoniazid derivatives as well as nicotinic acid hydrazide and picolinic acid hydrazide 
derivatives, as shown in Table 1. 
 To isolate IPH polymorphs from various crystallization techniques, followed by characterisation of 
these derivatives by physical techniques such as hot-stage microscopy (HSM), differential scanning 
calorimetry (DSC), single crystal and powder X-ray diffraction (SCXRD and PXRD) and infrared 
spectroscopy (IR). 
 To obtain SCXRD quality crystals of isoniazid derivatives and its pyridyl isomers for crystal structure 
determination. 
 To analyse the similarities and differences in intermolecular interactions and supramolecular clusters of 
the selected derivatives. 
 To observe thermal behavior in an attempt to survey the polymorphic space for each derivative. 
 
By applying the fundamental concepts of crystal engineering and supramolecular synthesis, it is envisaged that a 
diverse range of crystal structures can be obtained for the systems of interest. Ultimately, this study intends on 
contributing to current knowledge on these isoniazid derivatives, polymorphism, supramolecular aggregation 
and solid-state interactions.  
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Table 1: Detail of change in position of pyridyl nitrogen and different substituted acetophenones used in 
preparation of derivatives.  
 
 
 Pyridyl nitrogen 
4’- position 3’- position 2’- position 
Modification at 
 position R 
2-OH 
3-OH 
4-OH 
2-NH2 
3-NH2 
4-NH2 
2-OH 
3-OH 
4-OH 
2-NH2 
3-NH2 
4-NH2 
4-OH 
 
  
10 
 
CHAPTER 2 MATERIALS AND METHODS 
This chapter will describe the synthesis and crystallization protocols, crystal structure solution and physical 
characterisation procedures of this project. 
2.1 Synthesis and crystallization  
 
Scheme 1: Atomic labelling scheme of isonicotinic acid-(1-phenylphenylethylidene) hydrazide (IPH). The 
Roman numerals I – VI refer to the six expected polymorphs of IPH. 
2.1.1 Synthesis of isonicotinic acid-(1-phenylphenylethylidene) hydrazide (IPH)  
IPH was prepared in a yield of 95% by a Schiff Base reaction. Isoniazid (1.006 g, 7.335 mmol) 
(obtained from Sigma-Aldrich) and acetophenone (1.002 g, 8.343 mmol) were combined in a 100 ml 
round bottom flask, and dissolved in absolute ethanol (75 ml). To this mixture a catalytic amount of 
glacial acetic acid was added, and the solution was heated at reflux for 18 hours. A white solid 
precipitated from the reaction mixture which was filtered and washed with cold ethanol (3 × 25 ml). 
Characterisation of the product was determined by 
1
H and 
13
C NMR, IR and DSC (mp. 171.9°C) (see 
Appendices). Recrystallization was performed from using slow evaporation at ambient conditions with 
absolute ethanol as a solvent, yielding IPH V. 
2.1.2 Preparation of diffraction quality crystals of IPH  
For unequivocal proof of the existence of the IPH polymorphs, the crystal structures of each polymorph 
were essential. The first two diffraction quality crystals obtained were for IPH II and V. These crystals 
were recovered from slow cooling solution experiments using solvents acetonitrile and ethanol 
respectively.  IPH III crystals were recovered from rapid evaporation of a water/ethanol solution. It 
should be noted that these slow cooling solution experiments exclusively produced the respective 
polymorphs; however the rapid evaporation experiments produced a mixture of IPH III and V. Hence 
diffraction quality crystals of IPH III were separated out under the polarizing microscope. After 
exhaustive solution experiments, sublimation experiments were performed using a Kofler hot bench, 
from which colourless needle-like IPH I crystals were recovered for the first time. Following this, IPH 
IV and VI were never isolated or seen until HSM experiments were performed. After numerous 
attempts, IPH VI was recrystallised from melt on the hot-stage and IPH IV was grown on the hot-stage 
from melt by using a very slow cooling rate methodology. This was done to provide ample time to 
allow sufficient crystal growth for X-ray analysis, despite which the crystals were still incredibly small 
(maximum size: 0.56 x 0.046 x 0.040 mm) and obtained in very limited amounts. 
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2.1.3 Synthesis and crystallization preparations of derivatives 1 – 13  
Isoniazid (0.100 g, 0.729 mmol) and its pyridyl isomers were respectively mixed with the appropriate 
substituted acetophenone in an equimolar ratio, and dissolved in absolute ethanol (15 ml); these mixtures were 
then stirred at room temperature for 18 hours. The crude residue was filtered, and then washed with cold 
ethanol. Crystallization was achieved by slow evaporation of various solvents (see Table 2). Multiple 
crystallization experiments for 11 were not successful and suitable crystals for structure determination were 
never obtained. The melting points for each compound determined from DSC experiments are presented in 
Table 2. 
 
Scheme 2: Compounds 1 – 13 were chosen to study the effects of donor modification and placement of pyridyl 
nitrogen on the supramolecular aggregates.   
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Table 2: Crystallization solvents and melting points for the isoniazid derivatives. 
Compound Modification Crystallization solvent Melting point (°C) 
1 2-OH ethanol 165.5 
2 3-OH ethanol 157.0 
3 4-OH ethanol 289.0 
4 2-OH methanol  162.3 
5 3-OH ethanol 184.9 
6 4-OH ethanol 261.0 
7 2-NH2 ethanol 141.0 
8 3-NH2 ethanol 144.7 
9 4-NH2 1-propanol 223.6 
10 2-NH2 methanol 162.4 
11 3-NH2 N/A 152.2 
12 4-NH2 methanol 198.9 
13 2-OH methanol 261.7 
 
2.2 Instrumentation 
2.2.1 Crystal data and X-ray structural analysis  
The Bruker D8 VENTURE PHOTON CMOS area detector diffractometer, equipped with a graphite 
monochromated Mo Kα1 radiation (50 kV, 30 mA), was used to collect all the intensity data. Crystal 
structures were collected at 173 K to achieve satisfactory thermal ellipsoids. The program SAINT+, 
vers. 6.02
60
 was used to integrate the data and the program SADABS was used to make empirical 
absorption corrections. Space group assignments were made using XPREP
60
 on all compounds. In all 
cases, the structures were solved in the WinGX
 
Suite of programs
61
 by direct methods using SHELXS-
97
61
 and refined using full-matrix least-squares/difference Fourier techniques on F
2
 using SHELXL-97.
61
 
All non-hydrogen atoms were refined anisotropically. Thereafter, all hydrogen atoms attached to N 
atoms were located in the difference Fourier map and their coordinates refined freely with isotropic 
parameters 1.5 times those of the ‘heavy’ atoms to which they are attached. All C-H hydrogen atoms 
were placed at idealised positions and refined as riding atoms with isotropic parameters 1.2 times those 
of the ‘heavy’ atoms to which they are attached. Diagrams and publication material were generated 
using ORTEP-3,
62
 PLATON
63
 and DIAMOND.
64
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2.2.2 Powder X-ray diffraction 
 Powder X-ray diffraction data for IPH I, II, III and V  were collected at 293 K on a Bruker D2 Phaser 
diffractometer which employs a sealed tube Co X-ray source (λ = 1.5406 Å), operating at 30 kV and 10 
mA, and LynxEye PSD detector in Bragg-Brentano geometry. Powder X-ray diffraction confirmed that 
the single crystal structures obtained from solution and sublimation experiments were representative of 
the bulk material (See Appendix). 
2.2.3 Differential scanning calorimetry (DSC)  
Differential scanning calorimetry data (Table 1) were collected using a METTLER TOLEDO with 
aluminium pans under air. STAR SW 9.20 was used for instrument control and data analysis. 
Exothermic events were shown as peaks. Various heating and cooling protocols were performed as 
quantitative analysis of the polymorphs. The temperature and energy calibrations were performed using 
pure indium (purity 99.99%, m.p 156.6°C, heat of fusion 28.45 J g
-1
). 
2.2.4 Hot-stage microscopy (HSM)  
Hot stage microscopy experiments were performed using an Olympus SZ61 with stereo polarised light, 
and equipped with a Kofler hot stage. Various heating and cooling procedures for temperature induced 
crystal growth, melt and phase transitions were applied. 
2.2.5 Fourier-transform infrared (FT-IR) and Raman spectroscopy  
Infrared spectra for comparison of each form were collected for IPH I – III and V (see Appendices for 
spectra) using a Bruker Vertex 70 equipped with an ATR (MVP-Pro) sample handler. The experiment 
measured from 3500 cm
-1
 to 400 cm
-1
 and major peaks were assigned using OPUS 6.5. Infrared spectra 
of IPH IV and VI were not collected as sufficient quantities for IR experiments were never isolated. 
Complementary Raman spectra were collected for IPH I – III and V (see Supporting Information for 
spectra) using a Bruker MultiRAM FT-Raman Spectrometer fitted with an Nd-YAG laser and a 
Germanium diode detector. The experiment measured from 4000 cm
-1
 to 400 cm
-1
. Raman experiments 
were only performed on the forms with sufficient quantities and hence there are no spectra available for 
IPH IV and VI.   
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CHAPTER 3 POLYMORPHISM STUDIES OF ISONICOTINIC ACID-(1-
PHENYLETHYLIDENE) HYDRAZIDE 
This chapter describes the in-depth study taken of IPH. The study begins with crystal structure description for 
each polymorph, and is then followed by delineating the phase relationships between each polymorph of IPH. 
3.1 Introduction 
To date, only one crystal structure of isonicotinic acid-(1-phenylphenylethylidene) hydrazide  has been 
reported in the literature.
65
 Five additional forms have been isolated in this study (all stable at room 
temperature), and their crystal structures have been determined. The six forms have been labelled as 
IPH I – VI, in a sequence of highest to lowest melting points. The previously known form is now 
known as IPH V. It should be noted that the isolation and subsequent determination of six different 
crystal structures for an organic compound is rare. For single component molecular compounds, 5 -
methyl-2-[(4-methyl-2-nitrophenyl)amino]-3-thiophenecarbonitrile (the famous ROY) is a well-known 
highly polymorphic compound (seven crystal structures),
66
 and was recently superseded by flufenamic 
acid for the record of eight solved crystal structures.
67
 Another significant polymorphic system is that of 
triacetone-triperoxide (TATP), for which six crystal structures have been determined to date.
68
  In 
addition to solving the six crystal structures for IPH, the phase transformations and thermal 
relationships for IPH I – VI have been delineated, including the determination of thermodynamic 
parameters (enthalpies and temperatures of fusion and phase transitions). The use of HSM has been a 
critical tool in the study of these polymorphs. 
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Figure 8: The asymmetric units of IPH I – VI. The displacement ellipsoids are drawn at 50% probability level. H on C 
atoms are omitted for clarity. 
3.2 Crystal structure description of IPH I – VI 
3.2.1 Crystal structure of IPH I  
The asymmetric unit of IPH I consists of two pairs of symmetry independent molecules (A & B and C & D 
respectively) (Figure 8). These pairs hydrogen bond to one another using N-H∙∙∙O bonds to form discrete dimers 
with graph set notation 
69, 70
 𝑅2
2(8). Notable is the conformation with the amide H now syn to the carbonyl group 
(Figure 9). This is not seen in the other polymorphs. 
3.2.2 Crystal structure of IPH II 
The asymmetric unit of IPH II contains two symmetry independent molecules (Figure 8). In this crystal 
structure there are two rather distinct hydrogen bond patterns where molecule A will form a hydrogen bond 
pattern through the amide N1-H1∙∙∙O1 hydrogen bonds which creates an infinite chain along the c-axis of the 
unit cell, graph set C(4). Molecule B forms a dimer using the hydrazide hydrogen and pyridine nitrogen (N1-
H1∙∙∙N2). This cyclic dimer has graph set notation 𝑅2
2(14) (Figure 9). The two molecules themselves have no 
hydrogen bonding interactions between them. IPH II is the only polymorph in which the pyridine nitrogen is 
involved in hydrogen bonding. 
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3.2.3 Crystal structures of IPH III - VI  
The unit cell of IPH III has the longest cell axis of all the polymorphs, yet the asymmetric unit consists of only 
one symmetry independent molecule, resulting in a Z of 8 (Table 3) as seen in IPH I and II above. The 
asymmetric units of IPH IV – VI all have one molecule in a general position, with Z of 4 (Figure 8). The 
hydrogen bonding pattern for all these forms is a C(4) chain as seen in molecule A in IPH II (Figure 10). 
 
Figure 9: Packing arrangements of IPH I – VI viewed along their respective axes. IPH I demonstrates significant twisting of 
the pyridine ring relative to the carbonyl motif to facilitate dimerization hydrogen bonding. A common chain hydrogen bond 
motif is observed throughout the remaining polymorphs (with exception to IPH II co-forming a dimer by hydrogen 
bonding). Despite this commonality the unit cell parameters differ from polymorph to polymorph. 
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Figure 10: Hydrogen bond patterns for polymorphs IPH I – VI. These hydrogen bond patterns are used as a point of 
reference to juxtapose the conformational twisting of each polymorph. 
Table 3: Crystallographic data for IPH I – VI. 
*All crystals obtained for each polymorph were colourless in appearance.  
Compound I II III IV V VI 
Formula C14H13N3O1 C14H13N3O1 C14H13N3O1 C14H13N3O1 C14H13N3O1 C14H13N3O1 
Mr 239.27 239.27 239.27 239.27 239.27 239.27 
Crystal size 
[mm
-3
] 
0.40 x 0.061 
x 0.020 
0.55 x 0.28  
x 0.10 
0.42 x 0.11  
x 0.050 
0.56 x 0.046 
x 0.040 
0.45 x 0.20  
x 0.060 
0.42 x 0.37  
x 0.040 
Crystal 
habit
*
 
Needle Prism Needle Needle Plate Block 
T [K] 173(2) 173(2) 173(2) 173(2) 173(2) 100(2) 
System Triclinic Monoclinic Orthorhombic Monoclinic Monoclinic Monoclinic 
Space 
group 
P-1 P21/c Pbca P21/c P21/c P21/c 
a [Å] 9.7360(6) 10.211(2) 6.3540(4) 10.621(2) 25.899(1) 13.488(2) 
b [Å] 9.8752(6) 30.331(7) 7.6624(6) 14.442(2) 5.5463(3) 9.6611(1) 
c [Å] 26.154(2) 8.2353(2) 49.231(3) 8.2589(2) 8.3187(4) 9.3604(1) 
α [°] 92.856(4) 90 90 90 90 90 
β [°] 100.29(4) 110.19(1) 90 109.62(5) 95.876(4) 90.183(5) 
γ [°] 91.291(4) 90 90 90 90 90 
V [Å
3
] 2469.8 2393.9(9) 2397.0(3) 1193.3(3) 1188.7(1) 1219.7(3) 
Z / Z’ 8 / 4 8 / 2 8 / 1 4 / 1 4 / 1 4 / 1 
ρ [g.cm-3] 1.287 1.328 1.326 1.332 1.337 1.303 
R1 / wR2 0.0559/ 0.122 0.0400/ 0.113 0.0425/ 0.113 0.0532/ 0.107 0.605/ 0.148 0.0729/ 0.193 
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3.3 Phase relationships  
3.3.1 Hot-stage microscopy of IPH 
Four major phase transitions were observed and studied for IPH (Figure 11 – 13). Two phase transition cycles 
are presented and a video showing the phase transitions on thin film samples in action is available in the 
supplementary information. Beginning with IPH V, an endothermic transition of IPH V to III is followed by 
means of a large single crystal, recovered from bulk crystallization after the synthesis of the compound (Figure 
11). The onset of this transition occurs at 129°C and is irreversible upon heating and cooling to room 
temperature.  Additional phase transitions are observed in thin-film preparations. 
 
Figure 11: Plate-like crystal of IPH recovered from bulk recrystallization. Photograph a) shows IPH V before onset 
transition temperature (129°C), whilst b) shows the transition with the encroaching wave front (yellow arrows) in the crystal. 
c–d) shows the progress of the phase transition until the crystal has completely transformed into IPH III. 
When a thin-film of IPH is taken from melt and allowed to recrystallise, four concomitant forms of IPH I, III, 
IV and VI are produced (Figure 12). The recrystallization process occurs at around 129°C with relative mass 
proportions of each form ranging from bulk coverage to only a few seed crystals within the thin film sample. 
Recommencing the heating cycle, after cooling to room temperature, an initial phase transition occurs with an 
average onset temperature of (145 - 148°C), where IPH IV and VI undergo a phase transition into IPH III. 
Additionally during this process, IPH IV and VI transform into IPH I; however over this lower temperature 
range, the transition rate for these metastable forms is slower than that into IPH III. Therefore after this phase 
transition is completed at 155°C, a large fraction of IPH III with a relatively minor fraction of IPH I are now the 
only forms present in the thin-film sample. 
The second phase transition begins concurrently at 155°C with the end of the first phase transition, where IPH 
III reflects the transformation into IPH I. At ca 165°C the entire thin-film is converted into the high temperature 
form IPH I which then melts at 173°C. When this hot-stage cycle is repeated (bulk sample instead of thin-film) 
by fusing small amounts of IPH onto a glass slide coated with silicon oil, a different series of thermal events 
occurs (Figure 13). The advantage of such a preparation is that metastable islands are able to nucleate and grow 
and are not in contact with more stable form. After melting and subsequent cooling, IPH IV crystallises out as 
dendrites and needles without contact of the surrounding islands of IPH III and VI (Figure 13a – b). Therefore, 
it was possible to determine the homogeneous melting point of IPH IV at 145°C (Figure 3b) although islands of 
IPH III and VI are present in the close surrounding. Shortly thereafter at 150°C a phase transition begins in 
which IPH VI transforms into IPH III and is completed at 155°C.  
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Figure 12: Thin-film photo micrographs of the phase transition cycle of IPH as observed on the polarised microscope.  The 
cycle begins by recrystallization from melt, producing concomitant forms IPH I, III, IV and VI. Upon commencement of 
the heating cycle, the first phase transition (145°C) follows the encroaching wave front (red arrows) where IPH IV and VI 
transform into IPH III. This phase transition continues until IPH IV and VI are completely transformed into IPH III and I. 
The second phase transition (155°C) occurs with IPH III converting into IPH I until the sample is dominated by IPH I. 
Melting of IPH occurs with the onset of 173°C, and subsequent cooling allows for recrystallization and completion of the 
phase transition cycle. 
Owing from the paucity of IPH I seeds, no further transitions occur and this series of thermal events ends with 
the melting of IPH III at 163°C. A third alternative route may be taken after melt when a sample of IPH is 
quenched cooled to 25°C forming an amorphous solid (Figure 14). Upon heating to 65°C the amorphous solid 
crystallises into IPH I (Figure 14b). The recrystallization of the super-cooled melt into IPH I is quantitatively 
verified in the DSC trace of Figure 15.  
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Figure 13: Recrystallised islands of IPH and subsequent slow heating. Photograph a) shows pronounced recrystallization of 
IPH IV; b) shows concomitant recrystallization of IPH III, IV and VI; c) shows the onset of melting of IPH VI at 145°C, 
while a phase transition of IPH VI to III marked by red arrows occurs; d) shows the completion of the phase transition with 
the onset of 155°C. Finally, melting of IPH III (onset of 165°C) is shown in e) and f). 
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Figure 14: Super-cooled amorphous solid after quench cooling from melt. Photograph a) shows the amorphous solid with 
intentional breakage exemplifying rigidity; b) and c) show melting with the onset of 65°C of the amorphous solid with the 
presence of seed crystallites of IPH I; d) shows completed recrystallization of IPH I.  
3.3.2 Differential scanning calorimetry analysis and thermodynamic data 
The thermal behaviour observed on the hot-stage of all the forms of IPH was quantitatively verified and 
complimented using DSC experiments. In a large number of heating and cooling experiments, powdered IPH V 
was used as an initial starting point (for DSC traces beginning with other isolated IPH forms please see the 
appendices). Thermochemical data are calculated and summarised in Table 4.  
Table 4: Thermochemical data for polymorphs of IPH I – VI. 
[a] Calculated from crystal structure determinations at −100°C.  
  
  Form    
Property IPH I IPH II IPH III IPH IV IPH V IPH VI 
Tfus [°C] DSC 171.9 ±0.2 164.7 ±0.8 161.1 - - ~156 
HSM [°C] 173 165 162 145 - 155-158 
ΔfusH [kJ mol
-1
] 33.1 ±1.4 - - - - - 
transition to mod. - - → I → III → III → III 
ΔtrsH [kJ mol
-1
] - - −3.1 ±0.2    
Tcryst [°C] 128.9 - 128.9  - ~130 
ρ [g cm-3][a] 1.287 1.328 1.326 1.332 1.337 1.303 
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Figure 15: DSC traces of five successive heating /cooling runs beginning with IPH V. The initial trace shows the first phase 
transition (trs) from IPH V to III followed by a second phase transition of IPH III to I, and finally melting endotherm of IPH 
I. This is followed by the recrystallization of forms IPH I, III, IV and VI during the cooling runs. The second heating cycle 
shows phase transition of IPH IV, VI to III at 145°C and IPH III to I at 165°C respectively. The following heating/cooling 
cycles repeat the 2nd and 3rd heating and cooling cycles. The heating rate is 15 K/min. 
As shown in Figure 11, the phase transitions can be followed along the DSC trace in the first heating cycle 
(Figure 15) where a weak endothermic peak with onset temperature of 123°C indicates the phase transition of 
IPH V into III. At 163°C the inhomogeneous melting process (melting of IPH III and simultaneous 
crystallization of IPH I) is observed as an endo/exo process. The final thermal event during the heating cycle is 
the melting of IPH I at 172°C. The following cooling cycle introduces IPH IV and VI by means of concomitant 
recrystallization reproducibly over the temperature range 80 – 95°C. The successive heating/cooling cycles 
repeat the thermal behaviour shown in 2) heating and 3) cooling cycles, however the relative mass percentage of 
each form during the concomitant recrystallization process is altered. This in turn affects the magnitude of the 
phase transition and melting peak endotherms in these subsequent heating/cooling cycles. As a result of the 
nature of IPH VI, no further thermochemical data were obtained as the melting and transition endotherms 
cannot be resolved and this form was only ever isolated during hot-stage experiments in insufficient quantities 
for DSC analysis.  
 
Upon reheating the crystallised melt a weak endothermic event is visible around 157°C which is 
followed by the transformation of IPH VI to III, suggesting that the lower melting form IPH IV (145°C, 
see HSM experiments) underwent a solid-solid transformation to IPH III already at lower temperatures. 
The transformation of IPH IV into III is energetically very weak (as the representative peaks in the 
DSC traces are relatively small) and occurs over a broad temperature range. IPH I is the form with the 
highest melting point and lowest density. Therefore, we can assume that this form shows the highest 
entropy and a low thermodynamic stability (high free energy) at 0 K. From this, it can be inferred that 
IPH I is enantiotropically related to most, if not to all, of the other forms.  
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IPH V shows the highest density, and our data suggest that this polymorph is the thermodynamically 
stable form at room temperature. The observed endothermic transition of IPH V into IPH III is an 
indication of the enantiotropic relationship between these two forms (heat-of-transition rule
71
). 
Therefore there is a temperature range above room temperature where IPH III is more 
thermodynamically stable than IPH I and V. Furthermore, IPH II has the second highest melting point 
and its density is slightly higher than that of IPH III, suggesting that IPH II has greater stability with 
respect to IPH III. This suggests that there are three temperature regions containing the most 
thermodynamically stable form: IPH V at and below room temperature, IPH II above room temperature 
and below its melting point, and with IPH I right below its melting point. Consequently, IPH III, IV 
and VI are metastable in the entire temperature range. It should be noted that the IPH forms exhibit 
prolonged kinetic stability, which is indicated by the observation that IPH I, II and III did not transform 
to the room temperature stable form IPH V even after a storage period of one year.  
 
When taking a different approach after quench cooling, the super-cooled amorphous solid thermal 
activity can be quantitatively verified. The amorphous solid resulting from crash cooling of the melt 
shows a broad recrystallization exotherm upon reheating at approximately 65°C with melting of form 
IPH I only (Figure 16). Upon heating to 65°C an initial broad exothermic peak is present and is 
attributed to the crystallization of IPH I.  
 
Figure 16:  DSC trace of heating run for the super-cooled amorphous solid. At 65°C, a broad exothermic peak is observed, 
indicating a phase transition to IPH I. This is followed by eventual melting of IPH I. 
In conclusion six crystal structures have been determined for IPH. Additionally the structural arrangements have 
been explored, allowing discernment between each polymorph. Each form is stabilised by N-H···O hydrogen 
bond, with IPH II utilising the N-H···N hydrogen bond in addition to the amide-carbonyl hydrogen bond. 
Thermal analysis was performed and three major temperature ranges have been identified. These temperature 
ranges include the phase relationships and melting habit of the six polymorphs. To finalise the thermal picture of 
this polymorphic system, isolation of practical quantities of IPH IV and VI are required. 
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CHAPTER 4 SUPRAMOLECULAR AGGREGATION STUDIES OF ISONIAZID 
DERIVATIVES 
This chapter details and compares the crystal structure arrangements and subsequent supramolecular 
aggregation patterns for the pyridine based isoniazid derivatives. 
4.1 Introduction 
In recent studies
4, 5
 researchers have evaluated the antimicrobial activity of various analogues of N-isonicotinoyl 
arylaldehyde hydrazones. Therefore understanding the molecular structures may provide insight for researchers 
developing drugs of this type. Additional work on geometric isomers of N-isonicotinoyl arylaldehyde 
hydrazones have been used to study supramolecular structures arising from multiple hydrogen bonding nodes.
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For this study the hydrogen bonding patterns and supramolecular aggregates arising when N-isonicotinoyl 
arylketones hydrazones are modified with R = OH or NH2 at the ortho, meta and para positions of the phenyl 
ring, as shown in Scheme 2 will be followed. The molecule contains a number of hydrogen bonding functional 
groups arising from the pyridine ring and modified phenyl ring which are linked by a highly polar hydrazone 
group (Scheme 3). Possible interactions observed are O-H···N, N-H···N, O-H···O, N-H···O, N-H···π, π···π 
stacking and other weaker interactions such as C-H···N, C-H···O, C-H···N(pyridyl).   
 
Scheme 3: Numbering scheme and functional groups present within the isoniazid derivatives involved in 
hydrogen bonding. 
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In an attempt to create further diversity amongst the aggregates, the skeletal backbone of the molecule was 
altered by shifting the pyridyl nitrogen to the 3- position from the 4- position. The intention behind these 
modifications is to observe the hydrogen bond patterns manifested during crystallization when the hydrogen 
bond nodes are shifted around to different regions of the molecule. A third pyridyl isomer was also investigated 
in which the pyridyl nitrogen was placed in the 2- position (Scheme 2) to determine whether this  position for 
the pyridyl nitrogen could be useful for forming hydrogen bond nodes with neighbouring donors.  Overall the 
compounds were found to generate one, two, and three dimensional aggregates with no distinctive predilection 
for a single direction-specific intermolecular interaction, as will be discussed below. Even minor alterations to 
the skeletal backbone by shifting the pyridyl nitrogen one position in the ring can give rise to disparate 
supramolecular aggregates. As a result there is paucity in the prediction of crystal structures for geometric 
isomers. 
4.2 Structural determinations 
The atomic numbering scheme for phenol modification of the pyridine based series 1 – 6 is shown in Figure 17 
and amino modification series 7 – 12 in Figure 18 (13 is included within Figure 17, however it is the only 
compound with the pyridyl nitrogen modified at the 2- position). Crystallographic data for the series 1 – 6 and 7 
– 13 are shown in Tables 5 and 6 respectively. Hydrogen bonding interactions between each molecule are 
central to this study and therefore the donor and acceptor atoms are labelled consistently to make comparisons 
easier. Hydrogen bonding distances and angles for the series of compounds 1 – 6 and 7 – 13 are shown in Tables 
7 and 8 respectively.  The amide hydrogen is a robust donor as it may form hydrogen bonds either with the 
carbonyl or pyridyl acceptor of a neighbouring molecule. All compounds experience a degree of hydrogen 
bonding that varies in number from one hydrogen bond to five hydrogen bonds depending on the modification 
and position on the phenyl ring. The molecules form a variety of hydrogen bond patterns from discrete units to 
larger dimensional ones with many hydrogen bond rings. Selected torsional angles are present in Table 9. Each 
structure will be described briefly before overall trends and differences in structure generated by the 
modifications will be discussed. 
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Figure 17: The asymmetric units 1 – 6. The displacement ellipsoids are drawn at 50 % probability level; H on C atoms are 
excluded for clarity. 
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Figure 18: The asymmetric units 7 – 13 with 11 excluded. The displacement ellipsoids are drawn at 50 % probability level. 
H on C atoms are excluded for clarity. Note that 13 is the only 2-pyridyl modification made. 
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Table 5: Crystallographic data for compounds 1 – 6.   
 
1 2 3 4 5 
Crystal data      
Chemical formula C14H13N3O2 C14H13N3O2 C14H13N3O2 C14H13N3O2 C14H13N3O2 
Mr 255.27 255.27 255.27 255.27 255.27 
Crystal system, 
space group 
Monoclinic, 
P2/c 
Monoclinic, 
P21/c 
Monoclinic, 
P21/c 
Orthorhombic, 
Pca21 
Orthorhombic, 
Pbcn 
Temperature (K) 173 173 173 173 173 
a, b, c (Å) 19.2608 (6), 
8.2010 (3), 
17.4855 (6) 
21.750 (1), 
7.3308 (3), 
15.8777 (7) 
5.0912 (3), 
29.3716 (14), 
7.9954 (4) 
8.1855 (2), 
11.3169 (3), 
26.2683 (8) 
18.592 (9), 
7.961 (4), 
16.629 (12) 
β (°) 116.086 (1) 103.890 (3) 92.290 (4) 90 90 
V (Å3) 2480.62 (15) 2457.59 (19) 1194.65 (11) 2433.35 (11) 2461 (2) 
Z 8 8 4 8 8 
Radiation type Mo Kα Mo Kα Mo Kα Mo Kα Mo Kα 
µ (mm−1) 0.09 0.10 0.10 0.10 0.10 
Crystal size (mm) 0.48 × 0.37 × 
0.19 
0.36 × 0.33 × 
0.05 
0.49 × 0.21 × 
0.08 
0.59 × 0.25 × 
0.11 
0.51 × 0.07 × 
0.05 
      
Data collection      
Diffractometer Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
Absorption 
correction 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Tmin, Tmax 0.95, 0.99 0.96, 0.99 0.85, 0.95 0.969, 0.989 0.9, 0.99 
No. of measured, 
independent and 
observed [I > 2σ(I)] 
reflections 
74846, 5978, 
5340 
23608, 5268, 
3526 
8559, 2219, 
1552 
15720, 3008, 
2393 
10047, 2271, 
1763 
Rint 0.024 0.051 0.051 0.044 0.094 
(sin θ/λ)max (Å
−1) 0.661 0.635 0.606 0.661 0.606 
Final R indices [I > 
2θ(I)] 
0.0469 / 0.1297 0.0456 / 0.1192 0.0449 / 0.1011 0.0384 / 0.0949 0.0503 / 0.1418 
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Table 5: Crystallographic data for compounds 1 – 6 with 13 included (continued). 
    6 13    
Crystal data      
Chemical formula C14H13N3O2 C14H13N3O2    
Mr 255.27 255.27    
Crystal system, 
space group 
Orthorhombic, 
Pna21 
Monoclinic, 
P21/n 
   
Temperature (K) 173 173    
a, b, c (Å) 7.6592 (9), 
6.3516 (8), 
25.292 (3) 
7.4645 (3), 
19.1653 (8), 
9.0435 (4) 
   
β (°) 90 109.968 (3)    
V (Å3) 1230.4 (3) 1215.98 (9)    
Z 4 4    
Radiation type Mo Kα Mo Kα    
µ (mm−1) 0.10 0.10    
Crystal size (mm) 0.42 × 0.14 × 
0.03 
0.52 × 0.27 × 
0.21 
   
Data collection      
Diffractometer Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
   
Absorption correction Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
   
Tmin, Tmax 0.98, 0.99 0.962, 0.971    
No. of measured, 
independent and 
observed [I > 2σ(I)] 
reflections 
10335, 1147, 
1040 
11391, 2925, 
2078 
   
Rint 0.048 0.058    
(sin θ/λ)max (Å
−1) 0.606 0.661    
Final R indices [I > 
2θ(I)] 
0.0429 / 0.1023 0.0428 / 0.0982    
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Table 6: Crystallographic data for compounds 7 – 12. 
   7 8 9 10 12 
Crystal data      
Chemical formula C14H14N4O C14H14N4O C14H14N4O C14H14N4O C14H14N4O 
Mr 254.29 254.29 254.29 254.29 254.29 
Crystal system, 
space group 
Orthorhombic, 
P212121 
Monoclinic, 
Pc 
Monoclinic, 
P21/n 
Triclinic, 
P¯1 
Monoclinic, 
Pc 
Temperature (K) 173 173 173 173 173 
a, b, c (Å) 10.3960 (3), 
10.4585 (3), 
11.6963 (4) 
10.2885 (4), 
7.9628 (3),  
7.8303 (3) 
7.7689 (3),  
5.3398 (2),             
29.6584 (12) 
7.7053 (2), 
8.5521 (3), 
9.5984 (3) 
4.8332 (7),  
14.801 (2),  
8.7236 (15) 
β (°) 90 102.480 (2) 95.524 (3) 80.815 (1), 
89.535 (1), 
79.932 (1) 
96.960 (6) 
V (Å3) 1271.70 (7) 626.34 (4) 1224.65 (8) 614.65 (3) 619.45 (17) 
Z 4 2 4 2 2 
Radiation type Mo Kα Mo Kα Mo Kα Mo Kα Mo Kα 
µ (mm−1) 0.09 0.09 0.09 0.09 0.09 
Crystal size (mm) 0.5 × 0.38 × 0.26 0.59 × 0.14 × 
0.13 
0.53 × 0.17 × 0.12 0.37 × 0.25 × 
0.13 
0.41 × 0.18 × 
0.03 
Data collection      
Diffractometer Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
Bruker APEX-II 
CCD  
diffractometer 
Absorption 
correction 
Multi-scan  
SADABS (Sheldrick, 
1996) 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Multi-scan  
SADABS 
(Sheldrick, 1996) 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Multi-scan  
SADABS 
(Sheldrick, 
1996) 
Tmin, Tmax 0.965, 0.98 0.98, 0.998 0.89, 0.95 0.97, 0.98 0.96, 0.989 
No. of measured, 
independent and 
observed [I > 
2σ(I)] reflections 
10269, 1758, 1651 10435, 1525, 
1367 
9474, 2287, 1659 9868, 2265, 
2049 
8493, 1510, 
1350 
Rint 0.026 0.049 0.057 0.019 0.033 
(sin θ/λ)max (Å
−1
) 0.660 0.661 0.606 0.606 0.661 
Final R indices [I > 
2θ(I)] 
0.0318 / 0.0813 0.0329 / 0.0794 0.0456 / 0.1193 0.0401 / 0.1091 0.0430 / 0.1083 
 
31 
 
4.2.1 Previous determinations 
The structure of compound 9 (CSD REFCODE: SAZBOL) has been previously determined.
73
 It was found that 
the structure contains chains of hydrogen bonds of the type N-H···N and N-H···O. However the crystal structure 
was never described in detail and hence redetermination was required for this purpose as well as to obtain data 
for comparison purposes for this study. Compound 4 (YESTOG) is also found in the Cambridge 
Crystallographic Structural Database (CSD) and Zeitschrift für Kristallographie - New Crystal Structures,
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however the crystal structure contains a single water molecule in the asymmetric unit resulting in an altered 
crystal structure. Therefore it was necessary to determine and elucidate the anhydrous crystal structure for 
structural comparison. 
4.2.2 Structural aggregations of derivatised isoniazid with phenol donor 
Compound 1. Crystallises in the space group P21/c and contains two symmetry independent molecules (A and 
B) in the asymmetric unit (Figure 19). Molecules A and B are interrelated by N-H···N chain hydrogen bonds of 
the type –A-B-A-B- (of the graph set notation (C7)) with pyridyl acceptor of A and donor amide of B.  The 
phenol modification in the ortho position results in an intramolecular O-H···N hydrogen bond (with graph set 
notation (S6)) with the phenol hydrogen donor and the lone pairs of the hydrazone nitrogen as the acceptor. The 
intramolecular hydrogen bond reduces conformational flexibility of the backbone where it is aligned along the 
same plane as the phenyl ring.  
 
Figure 19: (a) Hydrogen bond motif of 1, where molecule A and B interchangeably form a hydrogen bond chain. (b) 
Viewing along the b-axis, the alignment of the backbone with the phenyl ring is observed.  
Compound 2. Crystallises in the space group P21/c with two symmetry independent molecules A and B in the 
asymmetric unit (Figure 20). Molecules A and B form chain linkages -A-B-A-B- by utilising the N-H···N 
hydrogen bond. When viewing along the b-axis of the unit cell, the molecules form additional hydrogen bonds 
creating columns of -A-A-A-A- and -B-B-B-B-. Column A is characterised by the N-H···N hydrogen bond 
utilising the amide donor and pyridyl acceptor. The column is further characterised by π···π (3.820(1) Å) 
stacking interactions occurring between the pyridine rings.  
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Column B is characterised by the O-H···O hydrogen bond utilising a phenol donor and carbonyl acceptor. It 
should be noted that the aromatic rings of molecule B do not exhibit π···π stacking interactions. The 
contribution of the phenol donor placed in meta position contributes to an overall large order hydrogen bond 
ring with graph set notation 𝑅6
6(60). These observed hydrogen bond rings result from the hydrogen bond 
connectivity of the columns internally and externally when joined together. 
 
Figure 20: (a) Two hydrogen bond columns are formed, including larger hydrogen bond rings are formed between 
connecting the columns by utilising the phenol donor in the meta position of the phenyl ring in 2. (b) Viewing along the b-
axis, the hydrogen bond rings are observed as well as the chains running along the ac direction. 
Compound 3. Crystallises in the space group P21/c with a single molecule in the asymmetric unit (Figure 21). 
This compound forms a N-H···O hydrogen bond between amide donor and carbonyl acceptor and O-H···N 
hydrogen bond between phenol donor (now in the para position) and pyridyl N acceptor along the b-axis. The 
amide hydrogen bond (2.31 Å) is the longer of the two hydrogen bonds where the phenol hydrogen bond is 1.94 
Å.  The molecules adopt a head to tail conformation and in conjunction with both hydrogen bond nodes a larger 
hydrogen bond ring system is observed with graph set notation 𝑅4
4(34).  
 
Figure 21: Compound 3 forms a 2D hydrogen bond array with amide donor and phenol donor in the para position. 
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Compound 4. With compound 4 the phenol donor is now changed to the ortho position and pyridyl nitrogen 
shifted to the 3-position in the pyridine ring (Figure 22). This compound crystallises in the space group Pca21 
with two symmetry independent molecules A and B in the asymmetric unit. Molecules A and B form an array of 
chain hydrogen bonds; by utilising the amide donor and carbonyl acceptor of the form N-H···O. The hydrogen 
bond chains form independently of one another in an -A-A-A-A- and -B-B-B-B- chains; however they do run in 
a parallel fashion along the b-axis of the unit cell. For both molecules A and B the phenol donor in the ortho 
position forms an intramolecular O-H···N hydrogen bond with the acceptor lone pair of the hydrazone nitrogen 
in the same way as seen in compound 1. Three π···π interactions are observed within this structure: the pyridine 
rings of both molecules A and B with a comparable distances of 4.094(1) Å for A and 4.106(1) Å for B; and 
between the phenol rings (Figure 22c) for A and B with distance 3.167(1) Å. 
 
Figure 22: Packing representations of compound 4. (a) With pyridyl nitrogen in the 3-position; parallel hydrogen bond 
chains are formed from symmetry independent molecules A and B. The hydrogen bond chains run along the a-axis with the 
pyridine rings involved in π···π interactions. (b) Hydrogen bond chains for A and B form along the a axis whilst these 
columns pack along each other along the c direction and alternate between column A and B along the b axis. (c) π···π 
interactions between phenol rings of molecule A and B are observed. 
Compound 5. This compound crystallises in the space group Pbcn with a single molecule in the asymmetric 
unit (Figure 23). A N-H···O hydrogen bond is formed between amide donor and carbonyl acceptor. When both 
the phenol donor and pyridine nitrogen are placed in the meta position, a O-H···O hydrogen bond chain is 
observed running along the c-axis.  These chain hydrogen creates a 2D network hydrogen bond and additionally 
a hydrogen bond ring with graph set notation 𝑅4
4(32). 
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Figure 23: Packing representations for compound 5. (a) Hydrogen bond chains are observed with the meta positioned 
phenol donor and 3-positioned pyridyl nitrogen. (b) A head-to-tail molecular aggregate is observed running along the c-axis.  
Compound 6. This compound crystallises in the space group Pna21 with a single molecule in the asymmetric 
unit (Figure 24). A N-H···O hydrogen bond is created between the amide hydrogen donor and carbonyl acceptor 
of the neighbouring molecule. With the phenol donor in the para position, it forms an O-H···H hydrogen bond 
with the pyridyl acceptor along the c-axis of the unit cell and contributes to an overall hydrogen bond 
ring (𝑅6
6(40)). When the packing motif is viewed along the b-axis, a head-to-tail zig-zag aggregation is 
observed including a 2D chain hydrogen bond in the direction of the a and c axes. 
 
Figure 24: (a) Compound 6 forms a 2D sheet of hydrogen bonds by utilising the amide donor and carbonyl acceptor pair 
along with the phenol donor and pyridyl N pair. By utilising six hydrogen bonded molecules, a larger ring is formed with 
graph set notation 𝐑𝟔
𝟔(40) while the centre of this ring formation provides further linkage of neighbouring molecules. (b) 
The head-to-tail molecular aggregation is observed with the hydrogen bond chains running in the a and c axis.  
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4.2.3 Structural aggregations of derivatised isoniazid with amino donor 
Compound 7. This compound crystallises in the P212121 space group with one molecule in the asymmetric unit 
(Figure 25). This molecule has an amino group in the ortho position on the phenyl ring. This modification acts 
as a potential bifurcated hydrogen bond donor and single acceptor. This molecule contains the largest number of 
hydrogen bonds amongst the isoniazid derivatives. The first hydrogen bond takes place between amide 
hydrogen donor and pyridyl N acceptor to form a N-H···N hydrogen bond chain with graph set notation C(7). 
The amino group forms an intramolecular N-H···N hydrogen bond by donating to the acceptor lone pair of the 
hydrazone nitrogen. The second hydrogen bond that the amino group forms is a N-H···O chain hydrogen bond 
by donating to a neighbouring carbonyl acceptor. The hydrogen bond chains form an infinite 2D array and 
combination of these hydrogen bonds forms a hydrogen bonded ring with graph set notation 𝑅6
6(26).  
 
Figure 25: (a) Compound 7 possesses the greatest number of hydrogen bonds amongst the isoniazid derivatives and forms a 
2D hydrogen bond chain array. (b) The 2D hydrogen sheets are demonstrated extending along the a and c axes forming 
larger hydrogen bond rings.  
 
Compound 8. This compound crystallises in the space group Pc with one molecule in the asymmetric unit 
(Figure 26). This compound has the –NH2 group on the meta- position of the phenyl ring. The amide hydrogen 
donates to the carbonyl acceptor of a neighbouring molecule to form a N-H···O chain hydrogen bond. The 
interaction between the amino hydrogen donor and pyridyl nitrogen acceptor may appear to be a hydrogen bond 
however the distance of DHA is more indicative of a short contact interaction (2.416 Å) with a DHA angle of 
160°.  The amino donor groups are all aligned in the direction of the c-axis of the unit cell.  
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Figure 26: (a) Compound 8 forms a hydrogen bond with amide donor and carbonyl acceptor. The N-H···N(pyridyl) is a 
short contact interaction (2.416 Å). (b) The meta positioned amino group always faces the same direction for each molecule.  
Compound 9. This compound crystallises in the space group P21/n with one molecule in the asymmetric unit 
(Figure 27). This compound has the amino donor group modified in the para- position of the phenyl ring. In this 
position the modification is utilised in this crystal structure by forming chain hydrogen bonds. By donating to 
the neighbouring pyridyl acceptor, it forms linear head to tail N-H···N chains with graph set notation C(14).  A 
short contact interaction is formed between amide donor and carbonyl acceptor (2.485 Å) with DHA of 166°. 
The unit cell is filled by two hydrogen bonded chains in parallel with carbonyl acceptors facing opposing 
directions to each other. Furthermore the crystal structure contains a second amino hydrogen interacting with the 
neighbouring phenyl ring N-H···π (2.830 A). 
 
Figure 27: (a) Compound 9 forms a hydrogen bond between the amino donor and pyridyl acceptor; however a short contact 
interaction is observed between the amide donor and carbonyl acceptor (2.485 Å). (b) A head-to-tail motif is observed with 
amino hydrogen donor contributing to a N-H···π (2.830 A) interaction.  
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Compound 10. This compound crystallises in the space group P¯1with one molecule in the asymmetric unit 
(Figure 28). This molecule has the pyridyl nitrogen placed in the 3- position whilst modifying the phenyl ring by 
the addition of an amino donor group to the ortho position. The amide hydrogen donor forms a N-H···N 
hydrogen bond by donating to the acceptor lone pair of the amino group. An intramolecular N-H···N hydrogen 
bond is formed between amino hydrogen donor and hydrazone acceptor. The second hydrogen coming off the 
amino group donates to the pyridyl acceptor of the neighbouring molecule in a N-H···N hydrogen bond. These 
hydrogen bonding nodes contribute to a hydrogen bond ring (exclusively containing nitrogen and hydrogen) 
with graph set notation 𝑅4
4(10). A secondary hydrogen bond ring is formed between four molecules with graph 
set notation 𝑅4
4(20). The carbonyl acceptors are only involved in short contact interactions and face opposite 
directions during the ring formations. Lastly, π···π interactions are observed between the phenyl and pyridyl 
rings (3.630 Å).  
 
Figure 28: (a) The ortho positioned amino group of compound 10 generates a variety of hydrogen bond rings. By utilising 
the amino, amide and hydrazone groups, a hydrogen bonded ring is formed using exclusively N-H∙∙∙N bonds. (b) With the 
pyridyl nitrogen in the 3- position, a larger hydrogen ring is formed by utilising the second amino hydrogen donating to 
pyridyl nitrogen. π···π interactions are shown in blue (c) The hydrogen bond interactions are placed in context with the rings 
forming side by side.  
Compound 12. This compound crystallises in the space group Pc with one molecule in the asymmetric unit 
(Figure 29) with a 50% disorder about the amino rings. This compound has the amino donor group attached to 
the para position of the phenyl ring. This position enables the molecule to crystallise in a 2D chain hydrogen 
bond array. The first N-H···O hydrogen bond chain extends along the a-axis of the unit cell where the molecule 
utilises the amide donor and carbonyl acceptor. The second N-H···N hydrogen bond is a chain hydrogen bond 
running along the b-axis of the unit cell where the amino group donates to pyridyl acceptor.  
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Only short contact interactions are observed for the second hydrogen coming off the amino donor. In 
conjunction with the first and second hydrogen bond chain described, a ring hydrogen bond with graph set 
notation 𝑅4
4(32) is formed.  
 
Figure 29: In compound 12 the amino donor placed in the para position with pyridyl nitrogen in the 3-position creates a 2D 
array of hydrogen bond chains (the amide donor and carbonyl acceptor utilised as the second hydrogen bond chain). A 
disorder of 50 % for the phenyl rings is observed.    
4.2.4 Structural description of pyridyl isomer at the 2- position 
Compound 13. This compound crystallises in the space group P21/n with one molecule in the asymmetric unit 
(Figure 30). With the pyridyl nitrogen placed at the 2-position it interacts favourably with the amide donor to 
form a short contact of 2.16 Å. This essentially ‘locks up’ the pyridyl nitrogen, preventing hydrogen bond 
formation to any neighbouring donors. A dimeric hydrogen bond ring is formed with the phenol donor and 
carbonyl acceptor O-H···O; notably, this hydrogen bond has a distance of 1.81 Å. The dimeric clusters are 
found to arrange themselves in a planar arrangement with a larger zig-zag formation proceeding throughout the 
unit cell.  
 
Figure 30: (a) Compound 13 forms a dimeric cluster with phenol donor and carbonyl acceptor. The pyridyl nitrogen forms 
an interaction with the amide hydrogen. (b) The linear dimeric clusters form zig-zag patterns proceeding along the b-axis. 
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Table 7: Hydrogen bond parameters for compounds 1 – 6. 
D-H···A D-H(Å) H···A (Å) D···A (Å) D-H···A (°) Symmetry Transformations 
1      
N(1A)-H(1A)···N(2B) 0.92(2) 2.11(2) 3.009(2) 167(2) x, y-1, z 
O(2A)-H(2A)···N(3A) 0.93(2) 1.73(2) 2.571(1) 150(2) - 
N(1B)-H(1B)···N(2A) 0.90(2) 2.10(2) 2.987(2) 169(2) - 
O(2B)-H(2B)···N(3B) 0.94(2) 1.71(2) 2.565(1) 149(2) - 
2      
O(2A)-H(2A)···N(2B) 0.84(1) 1.92(1) 2.754(2) 171(1) - 
O(2B)-H(2B)···O(1B) 0.84(2) 1.90(2) 2.733(2) 172(3) -x+1, y-1/2, -z+1/2 
N(1A)-H(2A1)···N(2A) 0.88(2) 2.16(1) 3.021(2) 165(2) -x, y+1/2, -z+5/2 
N(1B)-H(2B1)···O(2B) 0.88(1) 2.61(1) 3.249(2) 131(2) x, -y+3/2, z+1/2 
3      
N(1)-H(1)··· O(1) 0.88(1) 2.31(3) 3.099(2) 149(1) x+1, y, z 
O(2)-H(2)···N(2) 0.84(2) 1.94(1) 2.717(3) 154(3) -x+1, y-1/2, -z+3/2 
4      
N(1B)-H(1B)···O(1B) 0.83(3) 2.23(3) 2.987(3) 153(3) x-1/2, -y, z 
N(1A)-H(1A)···O(1A) 0.94(4) 2.10(4) 2.953(3) 149(3) x-1/2, -y+1, z 
5      
N(1)-H(1)···O(1) 0.90(3) 2.37(3) 3.200(3) 154(2) -x+1/2, y-1/2, z 
O(2)-H(2A)···N(2) 0.83(3) 1.99(3) 2.790(3) 162(3) x, -y+1, z-1/2 
6      
N(1)-H(1)···O(1) 0.91(5) 2.02(5) 2.896(4) 160(4) x-1/2, -y+1/2, z 
O(2)-H(2A)···N(2) 0.89(5) 1.85(6) 2.735(4) 175(5) -x+1, -y, z+1/2 
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Table 8: Hydrogen bond parameters for compounds 7 – 13. 
 
4.3 Comparisons of changing substituted positions  
Altering the donor position on the phenyl ring whilst keeping the pyridyl nitrogen constant (or shifting the 
pyridyl nitrogen) creates an unpredictable variety of supramolecular aggregations amongst the isomeric 
compounds. In order to advance structural prescience of the series, trends need to be identified. The phenol and 
amino donors with the exception of 2, 7 and 9 have a preference to form hydrogen bonds with the pyridyl 
nitrogen as opposed to the available carbonyl acceptor. Consequently it is observed that the carbonyl acceptors 
are frequently positioned towards the periphery of the molecule during hydrogen bond creation. The molecules 
utilise the carbonyl acceptor to form chain hydrogen bonds with amide donor. This orientation is noticed 
throughout the entire series. Notably when the pyridyl nitrogen is shifted to the 2-position the acceptor becomes 
unavailable to a form hydrogen bond with neighbouring acceptors. This effect of locking the aromatic ring in 
place with a hydrogen bond is observed in the interaction of the ortho donor and hydrazone acceptor locking up 
the ring. It is favourable for the 2-pyridyl ring to be orientated closest to the amide hydrogen as it is not only 
able to form a strained hydrogen bond interaction but the lone-pair repulsions are minimised between the 
carbonyl acceptor and pyridyl nitrogen. With these conditions in place it is safe to assume that the 2-pyridyl 
nitrogen and amide donor will always be unavailable for hydrogen bond formation to neighbouring molecules.  
The addition of a secondary hydrogen donor (amino) over a primary hydrogen donor (phenol) is only 
manifested in the generation of hydrogen bonds when placed in the ortho position of the phenyl ring. The 
hydrogen bond count is increased by the self-intramolecular bond available via the hydrazone.  
D-H···A D-H(Å) H···A (Å) D···A (Å) D-H···A (°) Symmetry Transformations 
7      
N(4)-H(4A)···O(1) 0.91(2) 2.13(2) 3.019(2) 163(2) x-1/2, -y+1/2, -z+1 
8      
N(4)-H(4B)···N(2) 0.91(4) 2.41(4) 3.289(3) 161(3) x+1,-y+1,z+3/2 
9      
N(4)-H(4B)···N(2) 0.96(2) 2.04(3) 3.001(3) 179(2) x+1/2, -y+1/2, z+1/2 
10      
N(1)-H(1)···N(4) 0.92(2) 2.13(2) 3.008(1) 159(1) -x, -y+1, -z+1 
N(4)-H(4A)···N(2) 0.90(2) 2.18(2) 3.059(2) 163(1) x-1, y+1, z 
N(4)-H(4B)···N(3) 0.89(2) 2.12(2) 2.707(1) 122(1) - 
12      
N(1)-H(1)···O(1) 0.90(3) 2.20(3) 3.004(3) 149(3) x-1, y, z 
13      
N(1)-H(1)···N(2) 0.86(2) 2.16(2) 2.632(2) 114(1)  
O(2)-H(2A)···O(1) 0.89(2) 1.81(2) 2.683(2) 168(1) -x+1, -y, -z 
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This effect induces planarity within the backbone and the phenyl ring of the molecule; however this planarity is 
only strongly felt up to the hydrazone nitrogen. Some compounds 1 and 4 may express this planarity as far as 
the carbonyl acceptor; however, this effect is only observed for the phenol donor. A trend is observed when the 
donor is placed in the meta position as it always forms a hydrogen bond with the pyridyl nitrogen. Whereas the 
phenol donor only donates to the pyridyl acceptor, in some cases the amino donor will donate a hydrogen to 
form an N-H···π interaction with a neighbouring aromatic ring. Therefore the identity of the donor in this 
position has little effect on maximising the hydrogen bond count within the crystal structure. When the donor is 
placed in the para position, chain hydrogen bonds running along the skeletal backbone of the molecule are 
observed. The shifting of nitrogen by one position in the pyridine ring does not disrupt hydrogen bond 
formation, however an alteration in supramolecular aggregation is observed.  When the position the amino 
group is poised in the direction of pyridyl lone pairs, it enables the orientation of the molecules to favourably 
enable the hydrogen bond chain formed between the amide donor and carbonyl acceptor.   
The conformations of each molecule can be described by defining the orientations of the rings and 
conformations of the backbone linking the aromatic rings (see Scheme 2 and Table 9).  The presence of the 
double bond constricts the conformational flexibility of the hydrazone functional group and it is found that all 
the compounds presented in this study are synthesised in the E conformation at the C-N double bond. 
Consequently H(1A) on the amide group is also found to be trans to the carbonyl acceptor O1 and shares the 
same region of space as the methyl group. The backbone (C-N-N-C) torsional angles deviate by no more than 
20° from 180° therefore these angles correspond to the observed trans amide linkages in all the compounds. 
These deviations from 180° suggest that the compounds are conformationally flexible when subjected to various 
packing conditions.  
Overall there is a greater deviation from the plane for the pyridyl ring than that of the phenyl ring with the 
greatest deviation experienced by molecule A in compound 1 (easily observed in Figure 19). However it is 
common amongst these compounds for the pyridyl ring to deviate out of plane with a mean deviation of 143°. 
The exception is compound 13 where the pyridyl ring is closest to the plane with 175°. This effect is observed 
by the locking in of the pyridyl nitrogen in the 2- position with the amide hydrogen. Overall there is less of an 
effect of shifting out of plane for the phenyl ring with mean deviation of 164° with notable exceptions of 5, 8 
and ring A of disordered compound 12. It is noticed most when the phenol donor is in the ortho position, the 
phenyl ring is aligned closest to the plane of the back bone for the series of compounds; whereas with the amino 
donor in the ortho the deviation from the backbone is greater.  
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Table 9: Selected torsional angles for compounds 1 – 13 (11 excluded). 
 Pyridyl ring (°) 
C5-C1-C6-N1 
Backbone (°) 
C6-N1-N3-C8 
Phenyl ring (°) 
N3-C8-C9-C14 
1A 121.01(1) 174.55(1) -177.65(1) 
B -124.05(1) -165.48(1) 170.90(1) 
2A -125.0(2) -166.43(2) -177.90(2) 
B -148.89(2) -176.24(2) 154.76(2) 
3 153.70(2) -161.78(2) -177.60(2) 
4A 151.2(4) -175.0(3) 177.0(2) 
B -138.8(4) 178.8(3) -177.1(2) 
5 -138.3(2) -178.51(2) 138.6(2) 
6 135.8(4) -174.6(3) 172.6(3) 
7 155.82(2) -162.78(1) 164.34(2) 
8 131.75(2) 178.17(2) 145.8(2) 
9 142.2(2) 159.93(2) 167.05(2) 
10 151.43(1) -171.27(1) -153.16(1) 
12A -150.7(2) 161.0(2) 149.2(3) 
B   -164.5(4) 
13 175.65(1) 177.26(1) -164.37(1) 
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CHAPTER 5 THERMAL BEHAVIOUR STUDIES FOR ISONIAZID DERIVATIVES 
This chapter introduces the thermal behaviour for the pyridine based isoniazid derivatives. Compounds that have 
been identified for further polymorphic investigation are highlighted. 
5.1 Introduction 
In addition to describing the supramolecular aggregates of the compounds 1 – 13, a preliminary study was 
undertaken to assess the polymorphic space for these compounds. The main idea behind this is determine 
whether or not the modification and/or position of the hydrogen bond donor disrupts or enhances the 
polymorphic ability observed compared to the highly polymorphic parent IPH. Selected compounds are 
presented below that show either interesting or promising thermal behaviour when heating from 25°C to its 
respective melting point and cooled back down to 25°C.  
5.2 Thermal behaviour of IPH   
The thermal behaviour of IPH has been comprehensively covered in Chapter 3. However, for comparison 
purposes, the phase relationships represented by DSC traces of IPH is reproduced here. For a full description of 
the events in Figure 15 refer to Chapter 3, and for representative traces for other heating cycles polymorphs of 
IPH refer to the Appendices. 
 
Figure 15: DSC traces of five successive heating /cooling runs beginning with IPH V. The heating rate is 15°C/min. 
 
5.3 Thermal events of interest for compounds 1 – 13 
Representative DSC traces for compounds 1 – 13 are given below. For the remaining traces not shown here, 
refer to the Appendices. Thermal events of interest for the compounds include super-cooled melts, higher 
melting points and new melting points after recrystallization from the melt.   
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5.3.1 Thermal events of interest for phenol modified compounds 
Figure 31 is chosen as a representative trace for compounds 1 – 3, 5 and 6 as these compounds do not 
recrystallise after melting and no further thermal events for such compounds are observed. It should be noted 
that compounds 3 and 6 with the modification placed in the para positions show significantly higher melting 
points compared to the rest of the phenol compounds.  
 
Figure 31:  DSC trace of 1 showing the lack of a crystallization exotherm on cooling, forming a super-cooled melt. 
Compound 4 is the first of the phenol modifications that potentially represents new forms as the melting point 
for the new phase after recrystallization from melting is significantly different to warrant further investigation. 
The compound does not crystallise upon cooling, however during the heating cycle at 128°C a broad exotherm 
is observed representing crystallization. Upon further heating a new melting point is observed (174°C) which 
indicates a new form. This lower melting point is continuously observed when repeating multiple heating and 
cooling cycles. Furthermore the crystallization of this new single form appears to be homogenous in the DSC 
pan as there is no indication of the phase present with the higher melting point.  
 
 
25 75 125 175
Temperature / oC 
Heating
Cooling
H
ea
t 
fl
o
w
 /
 m
W
 (
E
x
o
 u
p
) 
45 
 
 
Figure 32: DSC trace of 4. Recrystallization occurs only during the 2nd heating cycle, when a lower melting point for this 
form is observed. This thermal cycle is then repeated for the 3rd heating/cooling cycle.  
 
5.3.2 Thermal events of interest for amino modified compounds 
The DSC trace for compound 8 is shown in Figure 33 where there may be a secondary form crystallising for this 
compound. Upon cooling after melt a slight exotherm is observed at 113°C (could be recrystallization) and 
again when the heating cycle is recommenced (phase transition or further recrystallization). Thereafter a lower 
melting point is observed at 195°C as opposed to the original 203°C. Further heating and cooling do not 
significantly alter the thermal events; however, no exotherm peaks are observed during the cooling cycle.  For 
the 3
rd
 heating cycle a greater exotherm is observed, indicating that recrystallization is a single event as opposed 
to the separate crystallizations during the 1
st
 cooling and 2
nd
 heating. 
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Figure 33: DSC trace for 8 where the initial melting is observed as a doublet. Upon cooling and sequential heating 
crystallization occurs and a new melting point is observed. 
For compound 9 the first endothermic thermal event is observed at 97°C and thereafter the melting occurs at 
160°C. The sample from which the single crystal for crystal structure studies was obtained was the same sample 
used for the DSC thermal event determination, which suggests that the crystals are anhydrous. However the 
thermal event at this temperature is ambiguous to quantify as this temperature closely resembles that of 
vaporisation of water within crystal lattices. Despite this uncertainty other thermal events occur during the 
cooling and following heating cycles. During the cooling cycle a slight exotherm peak is observed at 77°C and a 
further exotherm during the heating cycle until melting is commenced at 149°C. Further cooling yields no 
significant events. 
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Figure 34: DSC trace for 9 where an initial thermal event occurs before melting. During cooling minimal crystallization is 
observed and upon heating a lower doublet melting point is observed. 
The thermal events for 11 are indicative of decomposition at 154°C as no other thermal events are observed for 
this compound. This trace exemplifies the difficulties faced when trying to recrystallise this compound from 
melt in an effort to obtain X-ray structure quality crystals. The thermal events for 12 are shown in Figure 36 
with the first thermal event (onset of 78°C) represented as a broad endothermic event. This peak occurs around 
the region for the vaporisation of water, however the single crystal selected from this sample was determined to 
be anhydrous; further examination is required. After melting no further events are observed which is akin to the 
thermal behaviour of compound 7. Overall the compounds exhibit significantly less polymorphic behaviour over 
ambient and melting point temperatures. It should be noted that the DSC traces for IPH I, II and III initially 
(see appendices) show no significant thermal behaviour upon heating. However during the cooling cycle the 
sample will revert to the phase cycle observed in Chapter 3 and hence still shows significant polymorphic 
behaviour.  
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Figure 35: DSC trace exemplifying decomposition of 11. 
 
 
Figure 36: DSC trace for 12 where a thermal event occurs with the onset of 78°C thereafter which melting occurs. During 
cooling, crystallization is not observed. 
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CHAPTER 6 CONCLUDING REMARKS AND FUTURE WORK 
6.1 Concluding remarks 
Polymorphism is a well-known phenomenon that requires significant attention during pharmaceutical 
production as a result of its not predictable appearance. An extreme example of polymorphism in drug 
compounds has been shown by the investigation of IPH, where six polymorphs of IPH have been identified, 
characterised and described, when initially only one crystal structure was reported in the literature.
65
 Five 
additional solid state structures have been reported in the present investigation. The analysis of IPH by HSM 
illustrates that HSM is a powerful and versatile tool for the analysis of polymorphism of drug compounds. The 
functionality of HSM ranges from crystal growth and melting point analysis to qualitative descriptions of 
thermal phase transitions. Further analysis of this compound may yield more isolatable polymorphs, becoming a 
contender for the polymorphic crystal structure record. 
The addition of hydrogen bond donors and shifting of pyridyl position in the isoniazid derivatives result in 
diverse arrangements of molecular aggregations. The shifting of the pyridyl nitrogen atom around the ring 
induces a slight deviation in the trends of the hydrogen bond motifs; however the deviation is mostly observed 
when the pyridyl nitrogen is “locked away” at the 2- position of the pyridine ring becoming unavailable to form 
the hydrogen bonds as demonstrated in the structures with nitrogen at the 3- and 4- position. Higher dimensional 
motifs using combinations of hydrogen bonds are observed in the structures where the donor and acceptor are 
aligned in the appropriate manner for hydrogen bond formation. Compounds 1, 2, 3, 5, 8 and 11 are not viable 
targets for polymorph investigation by applying thermal methods used in this study. This is because the 
recrystallization requirements of these derivatives are often difficult to achieve as these compounds solidify as 
opposed to crystallising after melt. Therefore obtaining new polymorphic forms from the melt may prove to be a 
fruitless attempt. The overall observed thermal activity for these compounds indicate lack of polymorphic 
activity. It appears that the polymorphic tendency is reduced when a phenol donor is modified to the phenyl ring 
and more favourable when an amine group is present for polymorph screening and investigation. 
The polymorphic ability of IPH and the molecular interactions and aggregations of compounds 1 - 13 exemplify 
the application of crystal engineering on molecular structure. The opportunities arising from the nascent field of 
crystal engineering allows for in-depth crystal structure exploration. Compounds with potential for biological 
applications such as N-isonicotinoyl arylketone hydrazones are an important target to aim for when exploring 
molecular structure with crystal engineering.  
6.2 Future work 
To broaden the search for further polymorph elucidation, pressure induced structure determination may be 
applied as a function of constant temperature. This may unlock other unforeseen polymorphs as current work 
was performed only under ambient pressure. Compounds 4, 7, 9 and 12 exhibit the potential for the discovery of 
further polymorphs, and if further hot-stage and exhaustive solution experiments were to be applied, an array of 
polymorphs for these compounds may arise. Compound 11 may yet crystallise to afford structure determination 
quality crystals if the correct solvent system and surrounding conditions are met. Finally, it may be of 
considerable interest to perform polymorph propensity calculations through the CSD. 
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APPENDICES 
1.1 Supporting Information for polymorphism studies of IPH 
1.1.1 Representative DSC traces for IPH I – III  
IPH I 
 
Figure A1: Representative DSC trace for numerous experiments for the melting and cool of IPH I. The DSC trace 
exemplifies the single melting endotherm characteristic of IPH I. 
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IPH II 
 
Figure A2: Representative DSC trace for numerous experiments for the melting and cool of IPH II. The DSC trace shows 
the melting point of IPH II and subsequent recrystallization and melt of IPH I.  
 
IPH III 
 
Figure A3: Representative DSC trace for numerous experiments for the melting and cool of IPH III. The DSC trace shows a 
similar behaviour as IPH II; however the onset of melt for the endotherm has shifted to 161.1°C indicating a different 
melting point.   
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1.1.2 Powder X-ray diffraction patterns for forms IPH I – III and V  
IPH I 
 
Figure A4: PXRD of IPH I compared to PXRD of single crystal structure determination of IPH I. The experimental pattern 
was calculated at room temperature and the calculated pattern at 173 K. 
IPH II 
 
Figure A5: PXRD of IPH II compared to PXRD of single crystal structure determination of IPH II. The experimental 
pattern was calculated at room temperature and the calculated pattern at 173 K.  
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IPH III 
 
Figure A6: PXRD of IPH III compared to PXRD of single crystal structure determination of IPH III. The experimental 
pattern was calculated at room temperature and the calculated pattern at 173 K. 
 
IPH V 
 
Figure A7: PXRD of IPH V compared to PXRD of single crystal structure determination of IPH V. The experimental 
pattern was calculated at room temperature and the calculated pattern at 173 K.  
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1.1.3 FT-IR and Raman spectra of IPH I – III and V 
FT-IR spectra of IPH I – III and V 
 
Figure A8: FT-IR spectra of IPH I – III and V. A spectrum for IPH IV and VI is unavailable as result from the insufficient 
quantities recovered. 
Raman spectroscopy of IPH I – III and V 
IPH I 
 
Figure A9: Raman spectrum of IPH I. 
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 IPH II 
 
Figure A10: Raman spectrum of IPH II. 
IPH III 
 
Figure A11: Raman spectrum of IPH III. 
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IPH V 
 
Figure A12: Raman spectrum of IPH V. 
1.2 Supporting thermal activity information for supramolecular aggregate studies of isoniazid 
derivatives 
Compound 2 
 
Figure A13: Representative DSC trace for numerous experiments for the melting and cool of 2.  
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Compound 3 
 
Figure A14: Representative DSC trace for numerous experiments for the melting and cool of 3. 
Compound 5 
 
Figure A15: Representative DSC trace for numerous experiments for the melting and cool of 5. 
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Compound 6 
 
Figure A16: Representative DSC trace for numerous experiments for the melting and cool of 6. 
Compound 7 
 
Figure A17: Representative DSC trace for numerous experiments for the melting and cool of 7. 
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Compound 10 
 
Figure A18: Representative DSC trace for numerous experiments for the melting and cool of 10. 
Compound 13 
 
Figure A19: Representative DSC trace for numerous experiments for the melting and cool of 13. 
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